BRPI0518054A - composto ou um sal, estereoisÈmero ou derivado de n-óxido farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto - Google Patents
composto ou um sal, estereoisÈmero ou derivado de n-óxido farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BRPI0518054A BRPI0518054A BRPI0518054-6A BRPI0518054A BRPI0518054A BR PI0518054 A BRPI0518054 A BR PI0518054A BR PI0518054 A BRPI0518054 A BR PI0518054A BR PI0518054 A BRPI0518054 A BR PI0518054A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- stereoisomer
- derivative
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSTO OU UM SAL, ESTEREOISÈMERO OU DERIVADO DE NóXIDO FARMACEUTICAMENTE ACEITáVEIS DO MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO. Esta invenção diz respeito a uma nova classe de compostos, esquematizados abaixo, em queR,R,R,R¬4¬,R¬5¬,R¬6¬,R¬7¬,Densao nesta definidos, que são inibidores de proteína cisteina, incluindo, mas não limitando a, inibidores de catepsinas K, L, S e B. Estes compostos são úteis para tratar doenças em que a inibição da reabsorção óssea é indicada, tal como a osteoporose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63040504P | 2004-11-23 | 2004-11-23 | |
PCT/CA2005/001764 WO2006056047A1 (en) | 2004-11-23 | 2005-11-18 | Cathepsin cysteine protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518054A true BRPI0518054A (pt) | 2008-10-28 |
Family
ID=36497694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518054-6A BRPI0518054A (pt) | 2004-11-23 | 2005-11-18 | composto ou um sal, estereoisÈmero ou derivado de n-óxido farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto |
Country Status (24)
Country | Link |
---|---|
US (2) | US7407959B2 (pt) |
EP (1) | EP1817276B1 (pt) |
JP (1) | JP5055488B2 (pt) |
KR (1) | KR20070085435A (pt) |
CN (2) | CN102391151A (pt) |
AR (1) | AR055283A1 (pt) |
AU (1) | AU2005309267B2 (pt) |
BR (1) | BRPI0518054A (pt) |
CA (1) | CA2589085C (pt) |
DK (1) | DK1817276T3 (pt) |
ES (1) | ES2394618T3 (pt) |
IL (1) | IL183308A (pt) |
MX (1) | MX2007006136A (pt) |
MY (1) | MY137717A (pt) |
NO (1) | NO339125B1 (pt) |
NZ (1) | NZ554872A (pt) |
PE (1) | PE20061054A1 (pt) |
PL (1) | PL1817276T3 (pt) |
PT (1) | PT1817276E (pt) |
RU (1) | RU2399613C2 (pt) |
SI (1) | SI1817276T1 (pt) |
TW (1) | TWI353244B (pt) |
WO (1) | WO2006056047A1 (pt) |
ZA (1) | ZA200703530B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003219953B8 (en) * | 2002-03-05 | 2008-09-25 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
JP4991295B2 (ja) * | 2003-09-18 | 2012-08-01 | ビロベイ,インコーポレイティド | システイン・プロテアーゼ阻害剤としてのハロアルキルを含む化合物 |
US8013186B2 (en) * | 2004-12-01 | 2011-09-06 | Virobay, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
WO2006060810A1 (en) * | 2004-12-02 | 2006-06-08 | Schering Aktiengesellschaft | Sulfonamide compounds as cysteine protease inhibitors |
WO2006076796A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Frosst Canada Ltd. | Cathepsin k inhibitors and obesity |
EP2783687A1 (en) * | 2005-03-02 | 2014-10-01 | Merck Sharp & Dohme Corp. | Composition for inhibition of cathepsin K |
BRPI0609695A2 (pt) | 2005-03-21 | 2011-10-18 | Applera Corp | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia |
CA2602112A1 (en) * | 2005-03-22 | 2006-09-28 | Celera Genomics | Sulfonyl containing compounds as cysteine protease inhibitors |
EP2077869B1 (en) * | 2006-08-28 | 2015-02-25 | Akademia Medyczna Im. Piastow Slaskich We Wroclaw iu | A system for the extra-corporeal purification of blood of pathogenic enzymes |
US20100048717A1 (en) * | 2006-09-25 | 2010-02-25 | MERCK FROSST CANADA LTD, Merk & Co., Inc. | Cathepsin b inhibitors |
US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
WO2008042968A2 (en) * | 2006-10-04 | 2008-04-10 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
WO2009065098A1 (en) * | 2007-11-16 | 2009-05-22 | Velcura Therapeutics, Inc. | Use of cathepsin k antagonists in the treatment of bone cancer |
WO2010056877A2 (en) * | 2008-11-13 | 2010-05-20 | Virobay, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
US8324417B2 (en) * | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
CN106916091B (zh) * | 2015-12-24 | 2020-10-09 | 广东东阳光药业有限公司 | 组织蛋白酶k抑制剂及其用途 |
US10758559B1 (en) * | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
CA3107899A1 (en) * | 2018-08-02 | 2020-02-06 | Intervet International B.V. | Crystalline forms of n1-(1-cyanocycloproply)-n2-((1s)-1-{4'-[(1r-2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-2,2,2-trifluoroethyl)-4-fluoro-l-leucinamide |
AU2019312842A1 (en) | 2018-08-02 | 2021-02-04 | Intervet International B.V. | Process to make a selective cathepsin cysteine protease inhibitor |
EP3946332A1 (en) | 2019-04-05 | 2022-02-09 | Université de Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
CN112438972B (zh) * | 2019-08-29 | 2021-07-30 | 沈阳药科大学 | 组织蛋白酶抑制剂的医药用途 |
CN113462728B (zh) * | 2021-07-09 | 2024-06-07 | 浙江工业大学 | 一种利用土星轮头酵母制备(r)-1-(4-溴苯基)-2,2,2-三氟乙醇的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135508A (en) | 1997-11-05 | 2006-12-10 | Novartis Ag | Nitriles of dipeptide |
EP1372655B1 (en) * | 2001-03-02 | 2008-10-01 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
US7302587B2 (en) * | 2001-06-08 | 2007-11-27 | Matra Transport International | Secure computer system |
JP4343690B2 (ja) * | 2001-11-13 | 2009-10-14 | メルク フロスト カナダ リミテツド | プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体 |
AU2003219953B8 (en) * | 2002-03-05 | 2008-09-25 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
WO2004052921A1 (en) * | 2002-12-05 | 2004-06-24 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
JP4991295B2 (ja) * | 2003-09-18 | 2012-08-01 | ビロベイ,インコーポレイティド | システイン・プロテアーゼ阻害剤としてのハロアルキルを含む化合物 |
EP2783687A1 (en) * | 2005-03-02 | 2014-10-01 | Merck Sharp & Dohme Corp. | Composition for inhibition of cathepsin K |
-
2005
- 2005-11-11 AR ARP050104742A patent/AR055283A1/es not_active Application Discontinuation
- 2005-11-14 MY MYPI20055317A patent/MY137717A/en unknown
- 2005-11-16 TW TW094140285A patent/TWI353244B/zh not_active IP Right Cessation
- 2005-11-17 PE PE2005001349A patent/PE20061054A1/es not_active Application Discontinuation
- 2005-11-18 DK DK05808098.7T patent/DK1817276T3/da active
- 2005-11-18 SI SI200531613T patent/SI1817276T1/sl unknown
- 2005-11-18 PT PT05808098T patent/PT1817276E/pt unknown
- 2005-11-18 US US11/282,536 patent/US7407959B2/en active Active
- 2005-11-18 US US11/791,250 patent/US20070293578A1/en not_active Abandoned
- 2005-11-18 CA CA2589085A patent/CA2589085C/en active Active
- 2005-11-18 CN CN2011102515598A patent/CN102391151A/zh active Pending
- 2005-11-18 BR BRPI0518054-6A patent/BRPI0518054A/pt not_active IP Right Cessation
- 2005-11-18 PL PL05808098T patent/PL1817276T3/pl unknown
- 2005-11-18 WO PCT/CA2005/001764 patent/WO2006056047A1/en active Application Filing
- 2005-11-18 RU RU2007123611/04A patent/RU2399613C2/ru not_active IP Right Cessation
- 2005-11-18 CN CNA2005800399148A patent/CN101061093A/zh active Pending
- 2005-11-18 AU AU2005309267A patent/AU2005309267B2/en not_active Ceased
- 2005-11-18 EP EP05808098A patent/EP1817276B1/en active Active
- 2005-11-18 NZ NZ554872A patent/NZ554872A/en not_active IP Right Cessation
- 2005-11-18 MX MX2007006136A patent/MX2007006136A/es active IP Right Grant
- 2005-11-18 JP JP2007541606A patent/JP5055488B2/ja not_active Expired - Fee Related
- 2005-11-18 KR KR1020077011749A patent/KR20070085435A/ko active IP Right Grant
- 2005-11-18 ES ES05808098T patent/ES2394618T3/es active Active
-
2007
- 2007-05-02 ZA ZA2007/03530A patent/ZA200703530B/en unknown
- 2007-05-17 IL IL183308A patent/IL183308A/en not_active IP Right Cessation
- 2007-06-22 NO NO20073222A patent/NO339125B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0518054A (pt) | composto ou um sal, estereoisÈmero ou derivado de n-óxido farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto | |
NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
MY162157A (en) | Substituted indole mcl-1 inhibitors | |
BRPI0513565A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
ECSP056210A (es) | Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
BRPI0819703A2 (pt) | Uso de inibidores de proteína tirosina fosfatase e hormônio de crescimento humano, uso de igf1 e um inibidor de proteína tirosina fosfatase e composição de combinação farmacêutica para o tratamento de atrofia muscular e distúrbios relacionados | |
ECSP077397A (es) | Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad | |
BRPI0514390A (pt) | enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
ECSP088969A (es) | Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia | |
TR201900548T4 (tr) | Prolil hidroksilaz inhibitörleri ve kullanım yöntemleri. | |
BRPI0515261A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo | |
BRPI0510166A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
CL2004000647A1 (es) | Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am | |
BRPI0512253A (pt) | composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
WO2007024717A3 (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
BR0309345A (pt) | Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa | |
BR0311931A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente | |
NO20053783L (no) | Behandling av godartet prostatahyperplasi | |
DK1694318T3 (da) | (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum | |
BRPI0510167A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
EP1784173A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | |
UY31917A (es) | Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |